Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lil Woozy…. Thanks for filling us in 👍🏼
Yes it is…. I found Fidi that way. I wonder if Fidi is helping out with launch of InstaCash since they mention Mexico and South American Countries on their LinkedIn page
Ok thanks
Where did you find that
Yes…. and I believe we have. Do we like the share price drifting lower…. Heck No
But I’m not worrying about anything
Eric…. I look at it as if they have 2 1/4 million until April…. That’s 3 1/2 months before they have to come up with 3/4’s of a million…. We’ll if they need to raise money at the time
Hal…. great post because you’re stating facts. What you’re saying is basically all revenue in the past was beta revenue…. which means they were beta testing their Commerse Platform. They now state R&D is over…. which tells me the Spigot is finally open. We’ll see where it leads from here on out.
Your post on the other board stated mis-leading facts on Insider Share Ownership. That’s what bothered me
Have you gone to Fintel to see Pre and Post split Share Count…. It’s on that site
Keep posting…. Facts are well received from me
Yes and Hemrak commented on the Nuvei / Microsoft partnership…. It looks like congratulations 5 employees by name
Your test passed…. We’re glad to have you
I agree…. The potential is unlimited for Apptech
If someone can give me a stock with anything close to what is possible for Apptech “besides a Biotech” I’d love to here it
12924 shares and 73150 warrants as of today
I can and have done quite a bit exchanged shares for warrants
I’m game
Test…. Just seeing if I can post …. It seems some are having trouble signing up
Totally agree…. It’s not a positive look for future possible shareholders
Did you see the shares that the insiders own on Fintel
Type “Mark Guzman FinZeo” in search and open his LinkedIn page
Scroll down under activity till it says “Sell FinZeo’s Electronic Invoicing”
V …. Go type “Fintel APCX” in search and go to insiders
You’ll see before split adjusted and after from January 2022 for Like and Virgil
Yes…. Mark Guzman shows on LinkedIn they will share the revenue on Electronic Invoicing …. What your saying is possible
Don’t forget Steve
and that was me that picked up the 100 shares after hours at $1.56
I had to
Ed from yahoo
That’s why I’m expecting revenues from the FinZeo acquisition…. He stated they boarded 20 new ACH clients that week and that was four months ago
Let it drift lower and I’ll pick up more …. Not that I want to see it but I will take advantage of it
Have you found what I was trying to lead everyone to…. as far as Blake Collins from FinZeo
I picked up 3,000 shares at $1.57
Crazy that it’s drifting this low
Great…. you can also get previous trades here
Put “Blake Collins Finzeo” in search and read his LinkedIn comments from a month ago
Looks like some nice growth
FinZeo should be a nice fit with the Company
Can’t wait for Tuesday
Did I read the Tweet right, that the company is predicting millions in revenues in the next 22 to 18 months?
My post was from knowledge. Since Medbridge stepped aside in early 2016 and the company went dark, I've found a few positive things involving VGLS.
VGLS might not be well, but it's still alive and kicking
Well it seems a little fishy that there were about 100 posts this past couple weeks and it just dried back up. Well the Quarterly is out if anyone is interested.
I'm taking another hiatus for a while, but it would have been nice to discuss the recent events involving the company that hasn't been publicized.
Oh well
Nice to see some decent posts the past week. I figured I'd come back and get involved, since I haven't posted since last year.
I don't believe the trading today was because of the recent late filing since they do it every quarter. I'll try to add a post everyday if I have time and I have a lot to share.
As you state..."being an SEC filer is meaningful"...is the important thing. I totally agree and here is why. This is from a PDF of someone who could be interested in VGLS. Will only buy if SEC reporting and as you also state..."Guess we'll find out"
I am a portfolio manager that specializes in biotechnology and the life sciences. With a diversified background in these subjects, I combine this knowledge with my financial services expertise to provide asset growth opportunities to invest in companies who are focused on improving human life.
My search for superior companies is global. Investment recommendations may include smaller, entrepreneurial ventures to more mature, undervalued blue chip companies.
The assets held in an account have four layers of protection:
and here is one of them....2. Compliance with Securities and Exchange Commission (SEC) requirements,
With two and a half months left in our double or nothing bet, I still feel a partnership is coming.
The animal studies should be done or almost done and with the uplist coming, it's not a bad time for a partnership if anyone is interested in the VG1177 peptide.
It seems there has been enough success in other peptide work to have hopes.
Here is the company listed in the Form 10 amendment that VGLS is working with and take a look at their recent article. It all promising in the world of peptides!
http://chronicle.augusta.com/news/business/local-business/2014-06-03/ambiopharm-inc-expand-north-augusta-workforce-operations
A biopharmaceutical manufacturer rooted in North Augusta is expanding its workforce and operations to keep pace with an increased market demand.
AmbioPharm Inc., a contract peptide producer for drug companies across the country, is investing $5 million to double its manufacturing operations and boost the staff by about 20 employees by this fall, said Robert Geiger, the company’s vice president of quality.
“Our customers have become more successful, so we’ve become more successful,” said Jim Hampton, the company’s executive vice president of business development. “We have nearly 100 customers in various stages of clinical studies and pre-clinical studies.”
I noticed page 36 is new in the amendment but as far as anything else it would obviously take time to compare with the previous one.
A couple positives to note. New money has been invested recently in the past three months with shares not being issued for a year.
The one thing that I noticed elsewhere and would ask why is.... why put in for the Trademark "VG Energy" in August unless there are plans down the road. It only cost a hundred bucks but as I said, why do it?
The "VG Energy" Trademark Registration Certificate was issued September 9th, so they own the name. New address is Gray Ave., Santa Barbara
Check out links below to see
http://tsdr.uspto.gov/documentviewer?caseId=sn85211407&docId=SOU20140802143900#docIndex=4&page=1
http://tsdr.uspto.gov/documentviewer?caseId=sn85211407&docId=ORC20140909001607#docIndex=0&page=1
http://tsdr.uspto.gov/#caseNumber=85211407&caseType=SERIAL_NO&searchType=documentSearch
It's Football season and it's also game time for VGLS. We will know shortly...IMO...what the future holds for the company.
Of course I'm not happy about the share price, but without the company pumping, putting out PR's for no reason and with the company recently cleaning up the mess from pre-split days, I'm not that surprised with the share price.
Okay, now let's see what is going on. If you look at the company website, you'll see Investors have been updated as far as the Form 10. Also, look what's up with LYME.....Very Interesting!
Has the company updated Lyme Research Alliance?
I'm not sure if the date below for Lyme should be extended for 3 months since the animal studies have been extended 3 months
But...IMO...Game On!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
http://www.vglifesciences.com/investors/#filings
On June 20, 2014, the company filed a Form 10-12G with the Securities and Exchange Commission and, as of August 19, 2014, is required to make ongoing disclosures and reports under the SEC’s online EDGAR system including annual and quarterly reports on Form 10-QSB or Form 10-KSB, as well as Current Reports on Form 8-K. The company remains in the SEC comment period related to the June 20, 2014 filing
http://www.lymeresearchalliance.org/research_new_overview.html
?LRA funded the research team that recently announced the first-ever drug to treat long-term Lyme disease, securing FDA pre-approval to enter clinical trials, anticipated to begin in October, 2014.
First let me say the tides have turned. The companies on time and you're late putting it here. Just kidding!
So you think the company might go dark, really? They've been issuing incentive stock options to Medbridge employees plus the likes of Dr. Rosenberg and Marshall Phelps, who have been helping out with advancing VGLS. I think you're grasping since that's all the negative you can put on it.
The new investment from the management, to me says things are moving along well. That's not a ton of cash, but it sure is not chump change.
As far as T&T..... if I recall they tried to gain control of VGV-1 in the lawsuit. If they feel VGV-X/VG 1177 is as good or better, why wouldn't they want to hold shares?
Also, you've done your research, knowing Karen tried to commercialize her technology before Viral. Remember, that's before VG1177
Also, I know you keep wondering how much is Karen doing with her busy schedule, but testing is ongoing.
http://www.linkedin.com/in/alidivan
I am a Biomedical PhD candidate at the Texas A&M Health Science Center. I am working under the mentorship of Dr. Karen Newell-Rogers and I am an active member of the Center for Cell Death and Differentiation.
My primary interest is in the tick-borne infection called Lyme Disease. At the moment I am investigating the effects of Borrelia burgdorferi infection on lymphocytes in murine models. Previously our laboratory demonstrated that surface expression of the CD74 cleavage product CLIP is increased after TLR stimulation, and that this peptide acts as a survival signal for splenic and lymph node derived B-cells. I am interested characterizing differential changes in CLIP in different B cell and T cell subsets during acute, and late stage infection by Borrelia burgdorferi. Furthermore, I will be asking whether displacement of CLIP by a targeted non-self peptide will have any effect on immune responses, inflammation, and infection burden at different stages of the disease.
The end goal is to understand the relationship between infection and acquired autoreactivity in Lyme Disease models and to develop therapies for the treatment of affected individuals.